Year archive

Grand Pharmaceutical Group Limited — 2025 filings

All 64 regulatory filings released by Grand Pharmaceutical Group Limited (512) in 2025, sourced directly from the official regulator.

64 Filings

2025 Period

2025 filings (64)

Filing	Released	Lang
CONNECTED TRANSACTION: ACQUISITION OF THE ENTIRE EQUITY INTERESTS IN HEBEI YUANDA JIUFU BIOTECHNOLOGY CO., LTD. AND BAODING JIAHE FINE CHEMICAL CO., LTD. M&A Activity	2025-12-31	English
VOLUNTARY ANNOUNCEMENT: THE WORLD'S FIRST ADRENALINE NASAL SPRAY INTRODUCED BY THE GROUP FOR THE TREATMENT OF SEVERE ALLERGIC REACTIONS OBTAINS DRUG REGISTRATION CERTIFICATE Regulatory Filings	2025-12-29	English
VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCES THE WORLD'S FIRST ADRENALINE NASAL SPRAY FOR THE TREATMENT OF SEVERE ALLERGIC REACTIONS Regulatory Filings	2025-12-23	English
VOLUNTARY ANNOUNCEMENT: THE PHASE III STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE RDC TLX591-CDx SUCCESSFULLY ACHIEVES THE PRIMARY ENDPOINT Regulatory Filings	2025-12-21	English
VOLUNTARY ANNOUNCEMENT: THE GROUP'S INDEPENDENTLY DEVELOPED, BLOCKBUSTER, GLOBALLY INNOVATIVE RADIONUCLIDE-DRUG CONJUGATE, GPN01530, HAS BEEN APPROVED FOR CLINICAL TRIALS IN THE UNITED STATES Regulatory Filings	2025-12-17	English
VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S CLASS 1 INNOVATIVE TRADITIONAL CHINESE MEDICINE GPN01360 SUCCESSFULLY REACHES THE CLINICAL ENDPOINT Regulatory Filings	2025-12-08	English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2021 AND 2022 ANNUAL REPORTS Remuneration Information	2025-12-04	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2025 Share Issue/Capital Change	2025-12-01	English
VOLUNTARY ANNOUNCEMENT: GLOBAL INNOVATIVE COMBINATION PRODUCT RYALTRIS NASAL SPRAY IS APPROVED TO BE COMMERCIALIZED IN CHINA Regulatory Filings	2025-11-10	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2025 Regulatory Filings	2025-11-03	English
VOLUNTARY ANNOUNCEMENT: THE PHASE IIa CLINICAL STUDY CONDUCTED IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00884 HAS COMPLETED THE FIRST PATIENT ENROLLMENT Regulatory Filings	2025-10-26	English
VOLUNTARY ANNOUNCEMENT: THE REGISTRATION CLINICAL STUDY CONDUCTED IN CHINA OF THE GLOBAL INNOVATIVE TEMPERATURE-SENSITIVE EMBOLIC AGENT HAS COMPLETED ALL PATIENTS ENROLLMENT Regulatory Filings	2025-10-09	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2025 Regulatory Filings	2025-10-02	English
Notification Letter and Reply Form to Non-registered Shareholders - Notice of publication of Interim Report Report Publication Announcement	2025-09-24	English
INTERIM REPORT 2025 Interim / Quarterly Report H1 2025	2025-09-24	English
Notification Letter and Reply Form to Registered Shareholders - Notice of publication of Interim Report Report Publication Announcement	2025-09-24	English
VOLUNTARY ANNOUNCEMENT: TREPROSTINIL INJECTION (20ML: 50MG) IS GRANTED A DRUG REGISTRATION CERTIFICATE Regulatory Filings	2025-09-23	English
VOLUNTARY ANNOUNCEMENT: NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE INJECTION IS OFFICIALLY APPROVED IN EUROPE Regulatory Filings	2025-09-08	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2025 Share Issue/Capital Change	2025-09-05	English
CONTINUING CONNECTED TRANSACTION Regulatory Filings	2025-08-27	English
2025 INTERIM RESULTS ANNOUNCEMENT Interim / Quarterly Report H1 2025	2025-08-19	English
DATE OF BOARD MEETING Regulatory Filings	2025-08-05	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025 Regulatory Filings	2025-08-01	English
VOLUNTARY ANNOUNCEMENT: RESTRUCTURING OF THE SHAREHOLDING IN THE COMPANY BY THE CONTROLLING SHAREHOLDER GROUP Major Shareholding Notification	2025-07-28	English
VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN AN INTERNATIONAL MULTICENTER PHASE III CLINICAL TRIAL OBTAINS IMPLIED APPROVAL FROM THE NMPA Regulatory Filings	2025-07-22	English
SUPPLEMENTAL ANNOUNCEMENT TO CONTINUING CONNECTED TRANSACTIONS: BUSINESS COLLABORATION AGREEMENT Regulatory Filings	2025-07-17	English
VOLUNTARY ANNOUNCEMENT: THE WORLD'S FIRST NASAL SPRAY PRODUCT OF THE GROUP FOR THE TREATMENT OF DRY EYE DISEASE, OC-01, ACHIEVES THE FIRST BATCH OF COMMERCIAL PRESCRIPTIONS AFTER ITS OFFICIAL APP Regulatory Filings	2025-07-17	English
VOLUNTARY ANNOUNCEMENT: A NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE INJECTION IS OFFICIALLY APPROVED BY THE FDA AHEAD OF SCHEDULE Regulatory Filings	2025-07-07	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2025 Share Issue/Capital Change	2025-07-02	English
VOLUNTARY ANNOUNCEMENT: THE GROUP'S GLOBAL INNOVATIVE OPHTHALMIC DRUG CBT-001 COMPLETES THE ENROLLMENT OF ALL PATIENTS IN THE INTERNATIONAL MULTI-CENTER PHASE III CLINICAL TRIAL Regulatory Filings	2025-06-04	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2025 Regulatory Filings	2025-06-02	English
VOLUNTARY ANNOUNCEMENT: THE GROUP'S GLOBAL INNOVATIVE PRODUCT FOR THE TREATMENT OF DEMODEX BLEPHARITIS IS APPROVED FOR COMMERCIALIZATION BY MACAO ISAF OF CHINA Regulatory Filings	2025-05-25	English
VOLUNTARY ANNOUNCEMENT: THE GROUP'S WORLD-LEADING NUCLEAR MEDICINE R&D AND PRODUCTION BASE OBTAINS A CLASS A "RADIATION SAFETY LICENSE" AND IS ABOUT TO BE PUT INTO OPERATION Regulatory Filings	2025-05-18	English
VOLUNTARY ANNOUNCEMENT: THE PHASE III STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE RDC TLX591-CDX COMPLETES PATIENT ENROLLMENT AND DOSING AND ITS NDA IS SCHEDULED TO BE SUBMITTED THIS YEAR Regulatory Filings	2025-05-12	English
VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN INTERNATIONAL MULTICENTER PHASE III CLINICAL TRIAL IS ACCEPTED BY THE NMPA Regulatory Filings	2025-05-07	English
CLARIFICATION ON CHINESE VERSION OF VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE PRODUCT STC3141 SUCCESSFULLY REACHED THE CLINICAL ENDPOINT Regulatory Filings	2025-05-06	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2025 Share Issue/Capital Change	2025-05-06	English
VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE PRODUCT STC3141 SUCCESSFULLY REACHED THE CLINICAL ENDPOINT Regulatory Filings	2025-05-06	English
VOLUNTARY ANNOUNCEMENT: THE GROUP'S EARLY DETECTION PRODUCT FOR URINARY SYSTEM TUMORS ACHIEVES ITS FIRST COMMERCIAL PRESCRIPTION IN MAINLAND CHINA Regulatory Filings	2025-04-27	English
CONTINUING CONNECTED TRANSACTIONS: BUSINESS COLLABORATION AGREEMENT Regulatory Filings	2025-04-25	English
VOLUNTARY ANNOUNCEMENT: THE GROUP'S FIRST GENERIC FLUTICASONE PROPIONATE NASAL SPRAY IN CHINA APPROVED FOR COMMERCIALIZATION Regulatory Filings	2025-04-22	English
VOLUNTARY ANNOUNCEMENT: THE CLINICAL STUDY IN CHINA OF THE GLOBAL INNOVATIVE RDC GPN02006 ACHIEVED A MILESTONE BREAKTHROUGH Regulatory Filings	2025-04-21	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 10 APRIL 2025 Declaration of Voting Results & Voting Rights Announcements	2025-04-10	English
Final dividend for the year ended 31 December 2024 Notice of Dividend Amount	2025-04-02	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2025 Regulatory Filings	2025-04-01	English
VOLUNTARY ANNOUNCEMENT: AN INTERNATIONAL MULTI-CENTER PHASE III CLINICAL TRIAL IN CHINA OF THE INNOVATIVE RDC PRODUCT ITM-11 INTRODUCED BY THE GROUP HAS COMPLETED THE FIRST PATIENT ENROLMENT AND DOSIN Regulatory Filings	2025-03-19	English
Proxy Form For the annual general meeting to be held on Thursday, 10 April 2025 or any adjournment thereof Proxy Solicitation & Information Statement	2025-03-18	English
(1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS; AND (3) NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-03-18	English
NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-03-18	English
ESG Report 2024 Environmental & Social Information	2025-03-18	English
Annual Report 2024 Annual Report FY 2024	2025-03-18	English
Notification Letter and Reply Form to Non-registered Shareholders - Notice of publication of Annual Report and Circular Report Publication Announcement	2025-03-18	English
Notification Letter and Reply Form to Registered Shareholders - Notice of publication of Annual Report, Circular and Proxy Form Report Publication Announcement	2025-03-18	English
CLARIFICATION ANNOUNCEMENT - COMPANY BYE-LAWS Report Publication Announcement	2025-03-18	English
BYE-LAWS Governance Information	2025-03-18	English
Final dividend for the year ended 31 December 2024 Notice of Dividend Amount	2025-03-12	English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024 Earnings Release FY 2024	2025-03-12	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2025 Regulatory Filings	2025-03-03	English
VOLUNTARY ANNOUNCEMENT: UPDATE ON STRATEGIC INVESTMENT IN TELIX Transaction in Own Shares	2025-02-28	English
DATE OF BOARD MEETING Regulatory Filings	2025-02-28	English
CONNECTED TRANSACTION: PROPOSED PARTIAL EXERCISE OF THE RIGHT TO ACQUIRE THE REMAINING EQUITY INTEREST IN NANJING KAINITE MEDICAL TECHNOLOGY COMPANY LIMITED M&A Activity	2025-02-21	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2025 Regulatory Filings	2025-02-03	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2024 Regulatory Filings	2025-01-02	English
VOLUNTARY ANNOUNCEMENT: THE REGISTRATION CLINICAL STUDY CONDUCTED IN CHINA OF THE GLOBAL INNOVATIVE TEMPERATURE-SENSITIVE EMBOLIC AGENT HAS COMPLETED THE FIRST PATIENT ENROLLMENT Regulatory Filings	2025-01-02	English

Filings by year

2026 23 filings
2025 64 filings
2024 64 filings
2023 69 filings
2022 49 filings
2021 72 filings
2020 50 filings
2019 44 filings
2018 72 filings
2017 40 filings
2016 45 filings
2015 36 filings
2014 32 filings
2013 44 filings
2012 46 filings
2011 28 filings
2010 63 filings
2009 28 filings
2008 41 filings
2007 21 filings
2006 28 filings
2005 35 filings
2004 54 filings
2003 41 filings
2002 40 filings
2001 23 filings
2000 13 filings
1999 4 filings